Triple

T10291927
Position Surface form Disambiguated ID Type / Status
Subject andexanet alfa E241384 entity
Predicate approvedBy P807 FINISHED
Object European Medicines Agency E3950 NE FINISHED

How this triple was built (2 steps)

Every LLM step that produced this triple, in pipeline order — named-entity classification, the disambiguation choices (the exact options shown, with the pick highlighted), and the generated description. The batch + timestamp of each is in the Provenance table below.

NER Named-entity recognition gpt-5-mini
Instruction
Given a phrase, classify it is english named entity (e.g., persons, organizations, works of art) in Latin script, or not (e.g., literals, dates, URLs, verbose phrases). For disambiguation, the statement where the phrase occurs as object is also given. Please return a JSON object with `phrase` (string, the phrase being analyzed) and `is_ne` (boolean, indicating whether the phrase is a Named Entity).
Input
Phrase: European Medicines Agency | Statement: [andexanet alfa, approvedBy, European Medicines Agency]
NED1 Entity disambiguation (via context triple) gpt-5-mini-2025-08-07 
Target entity: European Medicines Agency
Context triple: [andexanet alfa, approvedBy, European Medicines Agency]
  • A. European Medicines Agency chosen
    The European Medicines Agency is the European Union’s regulatory authority responsible for the scientific evaluation, supervision, and safety monitoring of medicines for human and veterinary use.
  • B. European medicines regulatory authorities
    European medicines regulatory authorities are national and regional agencies in Europe responsible for evaluating, authorizing, and monitoring the safety, quality, and efficacy of medicinal products.
  • C. Committee for Medicinal Products for Human Use
    The Committee for Medicinal Products for Human Use is the European Medicines Agency’s expert body responsible for evaluating and providing scientific opinions on the safety, quality, and efficacy of medicines for human use in the European Union.
  • D. Committee for Proprietary Medicinal Products
    The Committee for Proprietary Medicinal Products was a former scientific committee of the European Union responsible for evaluating and issuing opinions on the quality, safety, and efficacy of human medicinal products before it was replaced by the European Medicines Agency’s current committee structure.
  • E. Committee for Herbal Medicinal Products
    The Committee for Herbal Medicinal Products is a scientific body within the European Medicines Agency that evaluates and provides guidance on the safety and efficacy of herbal medicines in the European Union.
  • F. None of above.
  • G. Unsure - the case is ambiguous/there is not enough information to decide.

Provenance (3 batches)

The batch behind each pipeline step, in order, with when it ran. Timestamps are batch-level — stages were processed in waves, so the object chain (NER → NED1 → NEDg → NED2) reads in order, but predicate / elicitation batches can sit in a different wave.

Step Stage Batch ID Status When
creating Elicitation batch_69d381aaafc08190af475ef58dc16aba completed April 6, 2026, 9:49 a.m.
NER Named-entity recognition batch_69d4d2d35f048190a215493acdf1f718 completed April 7, 2026, 9:48 a.m.
NED1 Entity disambiguation (via context triple) batch_69d6f85dcbac8190a2ac66354010e328 completed April 9, 2026, 12:52 a.m.
Created at: April 6, 2026, 11:42 a.m.